MedTrace Logo

Bioavailability of ABT-450 and ABT-267 With Ritonavir

NCT02052362 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-02-19

No results posted yet for this study

Summary

A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in combination with each other and Ritonavir(r).

Conditions

  • Absolute Bioavailability

Interventions

DRUG

ABT-450/r/ABT-267

ABT-450, ABT-267 and ritonavir

Sponsors & Collaborators

Principal Investigators

  • Armen Asatryan, MD · AbbVie

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052362 on ClinicalTrials.gov